Long-circulating lipoprotein-mimic nanoparticles for smart intravenous delivery of a practically-insoluble antineoplastic drug: Development, preliminary safety evaluations and preclinical pharmacokinetic studies

International Journal of Pharmaceutics

Volumn 493, Issue 1-2, 2015, Pages 439-450

  Tadros, Mina Ibrahim ^a   Al Mahallawi, Abdulaziz Mohsen ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Bovine serum albumin; Chlorambucil; Egg yolk lecithin; Intravenous delivery; Lipoprotein mimic nanoparticles

Indexed keywords

ANTINEOPLASTIC AGENT; BOVINE SERUM ALBUMIN; CHLORAMBUCIL; DRUG CARRIER; LIPOPROTEIN; NANOPARTICLE; PHOSPHATIDYLCHOLINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD VESSEL INJURY; COMPLEX FORMATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG SYNTHESIS; EGG YOLK; ELIMINATION HALF-LIFE; HEMOLYSIS; HISTOPATHOLOGY; HYDROGEN BOND; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MALE; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PLASMA CLEARANCE; PRIORITY JOURNAL; RABBIT MODEL; RAT; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DRUG EFFECTS; EAR; INTRAVENOUS DRUG ADMINISTRATION; PATHOLOGY; RABBIT; VASCULARIZATION; WISTAR RAT;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTINEOPLASTIC AGENTS; CHLORAMBUCIL; DRUG CARRIERS; EAR; HEMOLYSIS; LECITHINS; LIPOPROTEINS; MALE; NANOPARTICLES; RABBITS; RATS, WISTAR; SERUM ALBUMIN, BOVINE;

EID: 84939152983     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.08.011     Document Type: Article

References (49)

1. A.E. Ahmed, M. Koenig, and J.H.H. Farrish Studies on the quantitation of chlorambucil in plasma by reversed-phase high-performance liquid chromatography J. Chromatogr. B Biomed. Appl. 233 1982 392 397
2. S. Benita, and M.Y. Levy Submicron emulsions as colloidal drug carriers for intravenous administration - comprehensive physicochemical characterization J. Pharm. Sci. 82 1993 1069 1079
3. N. Brandhonneur, F. Chevanne, V. Vie, B. Frisch, R. Primault, M.F. Le Potier, and P. Le Corre Specific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages Eur. J. Pharm. Sci. 36 2009 474 485
4. H. Bunjes Lipid nanoparticles for the delivery of poorly water-soluble drugs J. Pharm. Pharmacol. 62 2010 1637 1645
5. A.N. ElMeshad, and M.I. Tadros Transdermal delivery of an anti-drug via w/o emulsions based on alkyl polyglycosides and lecithin: design, characterization, and in vivo evaluation of the possible irritation potential in rats AAPS PharmSciTech 12 1 2011 1 9
6. FDA, Center for drug evaluation and research (CDER), 2005. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Rockville, MD (http://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf).
7. F. Galisteo-González, and J.A. Molina-Bolívar Systematic study on the preparation of BSA nanoparticles Colloids Surf. B Bioint. 123 2014 286 292
8. S. Ganta, J.W. Paxton, B.C. Baguley, and S. Garg Pharmacokinetics and pharmacodynamics of chlorambucil delivered in parenteral emulsion Int. J. Pham. 360 1-2 2008 115 121
9. S. Ganta, P. Sharma, J.W. Paxton, B.C. Baguley, and S. Garg Pharmacokinetics and pharmacodynamics of chlorambucil delivered in long-circulating nanoemulsion J. Drug Target. 18 2 2010 125 133
10. H. Gao, S. Cao, C. Chen, S. Cao, Z. Yang, Z. Pang, Z. Xi, S. Pan, Q. Zhang, and X. Jiang Incorporation of lapatinib into lipoprotein-like nanoparticles with enhanced water solubility and anti-tumor effect in breast cancer Nanomedicine (London) 8 9 2013 1429 1442
11. ® S100-coatedpoly-(-caprolactonemicroparticles: preparation, characterization and in vivo evaluation in rats Drug Delivery 18 7 2011 523 535
12. S. Gunasekaran, S. Kumaresan, R. Arun balaji, G. Anand, and S. Seshadri Vibrational spectra and normal coordinate analysis on structure of chlorambucil and thioguanine Pramana J. Phys. 71 6 2008 1291 1300
13. M.J. Hawkins, P. Soon-Shiong, and N. Desai Protein nanoparticles as drug carriers in clinical medicine Adv. Drug Delivery Rev. 60 2008 876 885
14. S.K. Jena, C. Singh, C.P. Dora, and S. Suresh Development of tamoxifen-phospholipid complex: novel approach for improving solubility and bioavailability Int. J Pharm. 473 2014 1 9
15. Y. Kang, C. Yang, P. Ouyang, G. Yin, Z. Huang, Y. Yao, and X. Liao The preparation of BSA-PLLA microparticles in a batch supercritical anti-solvent process Carbohydr. Polym. 77 2009 244 249
16. F. Kratz Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J. Controlled Release 132 3 2008 171 183
17. F. Kratz, U. Beyer, T. Roth, M.T. Schütte, A. Unold, H.H. Fiebig, and C. Unger Albumin conjugates of the anticancer drug chlorambucil: synthesis, characterization, and in vitro efficacy Arch. Pharm. (Weinheim) 331 2 1998 47 53
18. F.Y.F. Lee, P. Coe, and P. Workman Pharmacokinetic basis for the comparative antitumour activity and toxicity of chlorambucil, phenylacetic acid mustard and ß, ß-difluorochlorambucil (CB 7103) in mice Cancer Chemother. Pharmacol. 17 1986 21 29
19. K. Löf, J. Hovinen, P. Reinikainen, L.M. Vilpo, E. Seppälä, and J.A. Vilpo Kinetics of chlorambucil in vitro: effects of fluid matrix, human gastric juice, plasma proteins and red cells Chem. Biol. Interact. 103 3 1997 187 198
20. Y. Lu, Y. Zhang, Z. Yang, and X. Tang Formulation of an intravenous emulsion loaded with a clarithromycin-phospholipid complex and its pharmacokinetics in rats Int. J. Pharm. 366 1-2 2009 160 169
21. H. Maeda, and Y. Matsumura Tumoritropic and lymphotropic principles of macromolecular drugs Crit. Rev. Ther. Drug Carrier Syst. 6 3 1989 193 210
22. K. Maiti, K. Mukherjee, A. Gantait, B.P. Saha, and P.K. Mukherjee Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats Int. J. Pharm. 330 1-2 2007 155 163
23. R. Matsuno, and K. Ishihara Integrated functional nanocolloids covered with artificial cell membranes for biomedical applications Nano Today 6 2011 61 74
24. K.M. McMahon, L. Foit, N.L. Angeloni, F.J. Giles, L.I. Gordon, and C.S. Thaxton Synthetic high-density lipoprotein-like nanoparticles as cancer therapy Cancer Treat. Res. 166 2015 129 150
25. A.C. Moffat, M.D. Osselton, and B. Widdop Clarke's Analysis of Drugs and Poisons in Pharmaceuticals, Body Fluids and Postmortem Material forth ed. 2011 Pharmaceutical Press London
26. M.J. O'Neil, P.E. Heckelman, C.B. Koch, and K.J. Roman The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals fourteenth ed. 2006 Merck & Co., Inc. Whitehouse Station, NJ
27. A. Patil-Gadhe, A. Kyadarkunte, M. Patole, and V. Pokharkar Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro-in vivo aerosol performance Eur. J. Pharm. Biopharm. 88 1 2014 169 177
28. Q. Peng, X.Q. Wei, X.R. Shao, T. Zhang, S. Zhang, N. Fu, X.X. Cai, Z.R. Zhang, and Y.F. Lin Nanocomplex based on biocompatible phospholipids and albumin for long-circulation applications ACS Appl. Mater Interfaces 6 16 2014 13730 13737
29. S. SalgIn, U. SalgIn, and S. BahadIr Zeta potentials and isoelectric points of biomolecules: the effects of ion types and ionic strengths Int. J. Electrochem. Sci. 7 2012 12404 12414
30. A. Schmidt, B. Bölck, M. Jedig, D. Steinritz, F. Balszuweit, K. Kehe, and W. Bloch Nitrogen mustard (Chlorambucil) has a negative influence on early vascular development Toxicology 263 1 2009 32 40
31. P. Sharma, S. Ganta, W.A. Denny, and S. Garg Formulation and pharmacokinetics of lipid nanoparticles of a chemically sensitive nitrogen mustard derivative: chlorambucil Int. J. Pharm. 367 1-2 2009 187 194
32. H. Song, S. Nie, X. Yang, N. Li, H. Xu, L. Zheng, and W. Pan Characterization and in vivo evaluation of novel lipid-chlorambucil nanospheres prepared using a mixture of emulsifiers for parenteral administration Int. J. Nanomed. 5 2010 933 942
33. C.S. Sweetman Martindale: the complete drug reference thirtyseventh ed. 2011 Pharmaceutical Press London
34. B. Tang, G. Fang, Y. Gao, Y. Liu, J. Liu, M. Zou, and G. Cheng Liprosomes loading paclitaxel for brain-targeting delivery by intravenous administration: in vitro characterization and in vivo evaluation Int. J. Pharm. 475 1-2 2014 416 427
35. S.A. Tayel, M.A. El-Nabarawi, M.I. Tadros, and W.H. Abd-Elsalam Positively charged polymeric nanoparticle reservoirs of terbinafine hydrochloride: preclinical implications for controlled drug delivery in the aqueous humor of rabbits AAPS PharmSciTech 14 2 2013 782 793
36. S.A. Tayel, M.A. El-Nabarawi, M.I. Tadros, and W.H. Abd-Elsalam Promising ion-sensitive in situ ocular nanoemulsion gels of terbinafine hydrochloride: design, in vitro characterization and in vivo estimation of the ocular irritation and drug pharmacokinetics in the aqueous humor of rabbits Int. J. Pharm. 443 1-2 2013 293 305
37. M.B. Tobin Chlorambucil K.A. Connors, G.L. Amidon, V.J. Stella, Chemical Stability of Pharmaceuticals second ed. 1986 John Wiley NY
38. L. Trynda-Lemiesz Paclitaxel-HSA interaction: binding sites on HSA molecule Bioorg. Med. Chem. 12 2004 3269 3275
39. M. Wacker Nanocarriers for intravenous injection-the long hard road to the market Int. J. Pharm. 457 1 2013 50 62
40. L. Wei, N. Marasini, G. Li, C.S. Yong, J.O. Kim, and Q. Quan Development of ligustrazine-loaded lipid emulsion: formulation optimization, characterization and biodistribution Int. J. Pharm. 437 1-2 2012 203 212
41. R. Wetzel, M. Becker, J. Behlke, H. Billwitz, S. Bohm, B. Ebert, H. Hamann, J. Krumbiegel, and G. Lassmann Temperature behaviour of human serum albumin Eur. J. Biochem. 104 1980 469 478
42. F. Xiong, C. Xiong, J. Yao, X. Chen, and N. Gu Preparation, characterization and evaluation of breviscapine lipid emulsions coated with monooleate-PEG-COOH Int. J. Pharm. 421 2 2011 275 282
43. Y. Xu, X. Jin, Q. Ping, J. Cheng, M. Sun, F. Cao, W. You, and D. Yuan A novel lipoprotein-mimic nanocarrier composed of the modified protein and lipid for tumor cell targeting delivery J. Controlied Release 146 3 2010 299 308
44. X. Yanyu, S. Yunmei, C. Zhipeng, and P. Qineng The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats Int. J. Pharm. 307 1 2006 77 82
45. D.A. Yardley nab-Paclitaxel mechanisms of action and delivery J. Controlled Release 170 2013 365 372
46. F. Yuan, M. Dellian, D. Fukumura, M. Leunig, D.A. Berk, V.P. Torchilin, and R.K. Jain Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size Cancer Res. 55 17 1995 3752 3756
47. L. Zhang, S. Zhang, S.B. Ruan, Q.Y. Zhang, Q. He, and H.L. Gao Lapatinib-incorporated lipoprotein-like nanoparticles: preparation and a proposed breast cancer-targeting mechanism Acta Pharmacol. Sin. 35 6 2014 846 852
48. H.Y. - Zhang, X. Tang, H.Y. Li, and X.L. Liu A lipid microsphere vehicle for vinorelbine: stability, safety and pharmacokinetics Int. J. Pharm. 348 2008 70 79
49. J. Zhou, X. Zhang, M. Li, W. Wu, X. Sun, L. Zhang, and T. Gong Novel lipid hybrid albumin nanoparticles greatly lowered toxicity of pirarubicin Mol. Pharm. 10 10 2013 3832 3841